Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, a holding subsidiary of Kelun Pharmaceutical (SZ:002422), announced on Monday that the new drug application (NDA) for its small molecule rearranged during transfection (RET) kinase inhibitor A400 (EP0031) has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
The product is intended for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC).
This acceptance for review is based on positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both 1L and 2L+ advanced RET-fusion positive NSCLC.
iLeukon reports FDA clearance of IND application for phase II study of ILKN421H in advanced NSCLC
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
BioDlink makes first international shipment of bevacizumab to Colombia
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps